CD274 and lung cancer: Durvalumab is an IgG1κ1 mAb that binds PD‐L1, with the characteristics of high selectivity and high affinity,70, 73 which has been approved for the treatment of non‐small cell lung cancer, urethral cancer, and extensive small cell lung cancer.